AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
On 17 August, AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig in combination with chemotherapy in first-line metastatic non-small…
Oncology
-
-
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda
AstraZeneca has ended a Phase III trial of its bispecific volrustomig pitted against MSD’s blockbuster Keytruda (pembrolizumab) in non-small cell…
-
UK Prime Minister to meet with brain cancer patient after research appeal
The UK's Prime Minister, Andy Burnham, has agreed to meet with a Team GB swimmer who suffers from brain cancer…
-
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Artificial intelligence (AI) was a hot topic on the agenda at the American Society of Clinical Oncology (ASCO) meeting 2026,…
-
China’s rapid rise in drug development casts a long shadow over US oncology
2026 marks a clear turning point for China’s position in the global clinical trials arena, particularly in oncology. At this…
-
Summit debuts longer-term ivonescimab data as it awaits FDA NSCLC decision
Summit Therapeutics has released more Phase III trial data for ivonescimab in non-small cell lung cancer (NSCLC) as it awaits…
-
Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data
Nuvation Bio’s glioma drug has touted a 36-month progression-free survival (PFS) rate of 79% with nearly 40 months of follow-up, with its advancement to…
-
Agenus’ metastatic colorectal cancer combo achieves 33% three-year OS rate
Agenus’s metastatic colorectal cancer (mCRC) combination therapy has continued to show benefit after three years of treatment, with a median…
-
Genmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trial
Genmab’s Phase III trial of a combination therapy including its bispecific T-cell engager (BiTE) combination, including Epkinly, has met its…
-
Novocure’s Optune Gio fails to show benefit at earlier stage
Novocure’s stock has dropped more than 15% after its Phase III glioblastoma study of Optune Gio failed to show benefit…
